Neurontin Marketing and Sales Practices Litigation. In 2010, Barry was part of the Boston trial team that obtained a
$142 million verdict for Kaiser Foundation, a non-profit health care provider, against Pfizer for deceptive marketing of Neurontin (an anti-epileptic) to physicians for unapproved uses for which it was not effective. The
landmark judgment was the first time a pharmaceutical company had been held liable under the RICO statute.
Vytorin/Zetia Marketing and Sales Practices Litigation. Barry represented consumers of these cholesterol medications in a case alleging that the manufacturer delayed publication of a study showing that the combination drug was no more effective than generic simvastatin in reducing arterial plaque and heart disease. The case settled in 2010 for $27 million.
Synthroid Marketing Litigation. Barry was co-lead counsel in a class action against the manufacturer of the popular thyroid medication, who suppressed the publication of a study showing that a less expensive generic could be safely substituted. The $88 million settlement was distributed to consumers in 2003.